Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are
limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the …

Background Infection is a key component of bronchiectasis pathophysiology.
Characterisation of the microbiome offers a higher degree of sensitivity and resolution than …

Bronchiectasis is a disease associated with chronic progressive and irreversible dilatation of
the bronchi and is characterised by chronic infection and associated inflammation. The …

Rationale: Although inflammation and infection are key disease drivers in bronchiectasis,
few studies have integrated host inflammatory and microbiome data to guide precision …

Bronchiectasis is a highly complex entity that can be very challenging to investigate and
manage. Patients are diverse in their aetiology, symptoms, risk of complications and …

Rationale: Emerging data support the existence of a microbial “gut-lung” axis that remains
unexplored in bronchiectasis. Methods: Prospective and concurrent sampling of gut (stool) …

Objective To review the airway microbiome in chronic obstructive pulmonary disease
(COPD), bronchiectasis and bronchiectasis‐COPD overlap (BCO). Data source and study …

Rationale: Although airway microbiota composition correlates with clinical measures in non–
cystic fibrosis bronchiectasis, these data are unlikely to provide useful prognostic information …

Background Bronchiectasis is accompanied by chronic bronchial infection that may drive
disease progression. However, the evidence base for antibiotic therapy is limited. DNA …

Introduction: Bronchiectasis is a chronic endobronchial suppurative disease characterized
by irreversibly dilated bronchi damaged by repeated polymicrobial infections and …